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Effects of two models of hypercalcemia on renal acid base metabolism.
The effects of two models of chronic hypercalcemia on renal acid-base
metabolism were studied in rats. In the first series of experiments, rats
were rendered hyperparathyroid by the autologous grafting of 20 to 24
parathyroid glands into a single recipient. Hypercalcemia (5.48 0.03
mEq/liter in high PTH animals, 4.96 0.06 mEq/liter in pair-fed
controls, P < 0.001) occurred as did metabolic alkalosis (plasma total
carbon dioxide 25.44 0.47 mEq/liter vs. 23.84 0.57 in controls, P <
0.05). The rise in total carbon dioxide was in part a renal tubular effect
since urine pH was lower (6.77 0,04 vs. 6.95 0.04, day 5, P < 0.01)
bicarbonaturia less (165 26 vs. 283 28 p.Lmoles/24 hr, day 5, P <
0.01) and titratable acid (TA) excretion increased (164 43.4 vs. 48.2
2.53 mEqI24 hr, day 5, P < 0.01) in hyperparathyroid animals vs. pair-
fed controls. To test the specific role of hypercalcemia versus PTH in
this effect, normoparathyroid animals were treated with 1,25 (OH)2
vitamin D3 or SHAM injected. Urinary cAMP was reduced in these
animals (0.030 0.004 moles/8 hr) compared to hyperparathyroid rats
(0.055 0.01 moles/8 hr P < 0.05) suggesting differences in PTH
levels. Hypercalcemia occurred in l,25(OH)2 vitamin D treated animals
as did increased plasma total carbon dioxide and urinary TA while
urinary bicarbonate excretion and urine pH were reduced. Because
hypercalcemia was associated with elevated total carbon dioxide in
both models, it is proposed that chronic hypercalcemia stimulated renal
acid excretion and in a sustained manner results in metabolic alkalosis,
at least in part, on a renal basis.
Effets de deux modéles d'hypercalcémie sur le métabolisme acidoba-
sique renal. Les effets de deux modCles d'hypercalcemie chronique sur
Ic mCtabolisme acido-basique renal ont dtd dtudid chez des rats. Dans
une premiere série d'expCriences, des rats onE étd rendus hyperparathy-
roldiens par Ia greffe autologue de 20 a 24 glandes parathyroIdes chez un
seul receveur. Une hypercalcemie (5,48 0,03 mEq/litre chez les ani-
maux a PTH ClevCe, 4,96 0,06 mEq/litre chez les contrOles nourris de
facon apariée, P < 0,001) est apparue en méme temps qu'une alcalose
mCtabolique (carbonique plasmatique total 25,44 0,47 mEq/litre,
contre 23,84 0,57 chez les contrôles, P < 0,05). L'élévation du
carbonique total était en partie due a un effet tubulaire renal puisque le
pH urinaire était plus bas (6,77 0,04 contre 6,95 0,04 au SC jour, P <
0,01), Ia bicarbonaturie moindre (165 26 contre 283 28 i.moles/j au
SC jour, P < 0,01) et I'excrétion de I'acidité titrable (AT) augmentde
(164 43,4 contre 48,2 2,53 mEq/j au SC jour, P < 0,01) chez les
animaux hyperparathyroldiens par rapport aux contrôles nourris de
facon apariCe. Afin de prCciser le role spécifique de l'hypercalcdmie par
rapport a celui de Ia PTH dans cet effet, des animaux normo-parathyrol-
diéns ont etC traitCs avec de Ia 1 ,25(OH)2 vitamine D3 ou traitCs de
facon factice. L'AMPc urinaire Ctait diminué chez les rats normopar-
athyroIdiens (0,055 0,01 mo1es/8hr, P < 0,05), suggCrant des
differences de PTH plasmatique. Une hypercalciurie est apparue chez
les animaux traitCs par Ia I ,25(OH)2 vitamine D parallClement a une
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dldvation du carbonique plasmatique total et de I'AT urinaire, tandis
que l'excrdtion urinaire des bicarbonates et Ic pH urinaire diminuaient.
Puisque l'hypercalcdmie s'accompagnait d'une ClCvation du carbonique
total dans les deux modCles, il est suggdrC que I'hypercalcCmie chron-
ique a stimuld l'excrCtion rCnale des acides, et, de facon prolongee, a
entrainC une alcalose mCtabolique en partie d'origine rCnale.
Despite the passage of nearly half a century since the report
of Ellsworth and Nicholson [1] demonstrating a bicarbonaturic
effect of parathyroid extract, the role of parathyroid hormone
(PTH) in acid-base balance remains controversial. Although
subsequent work has confirmed this acute effect [2, 3, 4],
systemic acidosis has not been produced by PTH infusion, nor
has the effect of chronic elevation of PTH on acid base balance
been well defined. In some studies, the phosphaturia induced
by PTH led to a rise in titratable acid excretion quantitatively
greater than the bicarbonaturia, so that total renal acid excre-
tion actually increased [5, 6].
In observations of patients with primary hyperpara-
thyroidism, hyperchloremic acidosis has been noted [1], but it is
an inconsistent finding [8]. When present, it may be related to
the concurrent renal failure or nephrocalcinosis seen in some
patients. The acidosis associated with osteomalacia has been
attributed to secondary hyperparathyroidism because the de-
fect in urinary acidification was corrected by treatment with
vitamin D and an elevation of serum calcium [9]. However,
because such patients were markedly hypophosphatemic, the
bicarbonaturia and acidosis associated with chronic phosphate
depletion [10, 11] may have been an important factor.
Finally, studies have documented a specific effect of acute
hypercalcemia to acutely increase renal bicarbonate reabsorp-
tion [12] and hydrogen ion secretion [13]. These effects would
be expected to produce a systemic alkalosis if maintained. In
the present study, a model of chronic hypercalceinic hyperpara-
thyroidism produced by parathyroid transplantation, as well as
chronic hypercalcemia induced by 1 ,25(OH)2 vitamin D admin-
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istration, have been used to characterize the chronic acid-base
effects of parathyroid hormone and hypercalcemia. Our studies
reveal that metabolic alkalosis is the predominant acid-base
disturbance in these conditions. The data suggest an important
role for hypercalcemia in the production of metabolic alkalosis,
in part through direct effects to stimulate renal acid excretion.
Methods
Hyperparathyroid model. These studies were performed in
150 to 250 g male Lewis or Fisher rats utilizing a modified
method of Gittes and Wells [14]. For any one experiment,
donor, recipient, and control rats were from the same strain.
Donor rats were anesthetized with 3.6% chloral hydrate, 0.1
1jj1100 g i.p.; the parathyroid glands were localized and mobi-
lized with the aid of a binocular dissecting microscope. After
harvesting, glands were stored on ice in a culture dish contain-
ing Hank's solution (Microbiological Associates, Walkervile,
Maryland) until 20 to 24 glands were accumulated. Recipient
rats were anesthetized lightly with ether, and a pouch was
created in the ventral surface of the lower limb musculature by
blunt dissection. The glands were placed in the pouch, the
pouch was closed with a single silk suture, and the skin incision
was closed with staples. In SHAM-operated controls, the
pouch was created and then closed with silk and staples in like
manner, but no glands were implanted.
Animals were housed in individual metabolic cages. Experi-
mental animals had free access to food throughout the study;
controls were pair-fed daily. All animals had access to distilled
water ad libitum and were allowed to acclimate to the metabolic
cages before any study was begun.
Hyperparathyroid hypercalcemic animals were fed a synthet-
ic diet (phosphorus free diet, ICN, Cleveland, Ohio) which was
supplemented to 0.6% calcium, 0.6% phosphorus. In some
studies the animals received a 1% calcium, 1% phosphorus diet,
but the data was similar with the two diets so results were
pooled. On day 0, experimental rats received parathyroid
transplants and control rats underwent SHAM operations.
Vitamin D model. 1 ,25-(OH)2 vitamin D-induced hypercalce-
mia was produced in rats by daily i.p. injections of 40 ng of 1,25-
dihydroxycholecalciferol (kindly supplied by Dr. W. E. Scott,
Hoffman-LaRoche, Nutley, New Jersey) in 25 l absolute
ethanol. Controls were pair-fed and received 25 l absolute
ethanol daily via i.p. injection.
Laboratory studies. Fed animals were bled from the retrorbi-
tal plexus or from the femoral vein under light ether anesthesia.
Urine collections were begun at 8 A.M. and were performed
under oil using thymol preservative. Urine samples for cyclic
AMP determinations were collected in glass vials kept chilled in
ice and were frozen until assayed by double antibody radio-
immunoassay kit (New England Nuclear, Boston, Massachu-
setts). Urine or plasma calcium, phosphate, sodium, potassium,
creatinine, pH, total carbon dioxide, and ammonia were deter-
mined as described previously from this laboratory [15]. Titrat-
able acid was determined by microtitration with sodium hy-
droxide. All measurements of total carbon dioxide, pH, and
urinary titratable acid levels were performed on fresh, unfrozen
samples. Total acid excretion was calculated as the sum of
ammonium and titratable acid excretion minus bicarbonate
excretion. Clearance and fractional excretions were calculated
in the usual manner. Statistical analyses were performed by
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Student t test or standard linear regression formulae. All data
are expressed as mean SEM.
Results
Hyperparathyroid hypercalcemia. As shown in Figure 1,
transplantation of parathyroid glands into recipient animals (N
= 10) produced sustained hypercalcemia when compared to
pair-fed controls (N = 10). Significant hypercalcemia was seen
as early as 2 days postsurgery. By day 7, the hyperparathyroid
rats had a mean plasma calcium of 5.48 0.03 mEq/liter vs.
4.96 0.06 mEqfliter (P < 0.001) for the pair-fed controls. Also
the level was significantly higher from day 0 value in hyperpar-
athyroid animals, 5.28 0.02 mEq/liter P < 0.05 but was not
different in controls (Fig. 1). It should be noted that given the
differences which may occur from day to day in animals
undergoing metabolic balance studies, it is most appropriate to
compare the two groups of animals on the same diet and
evaluate how changes occur with time rather than to compare
pre-surgery or drug administration values to subsequent values
found following such manipulations. Any changes seen in the
control group are likely due to the stresses of surgery, reduction
of dietary intake which frequently accompany the experimental
maneuver, or other unknown factors. While comparisons are
provided between basal and postexpenmental periods, we
emphasize the importance of comparing animals which are pair-
fed for the most precise analysis of the data.
The hypercalcemic animals were transiently hypercalciuric
(days 5 and 6). On day 5, calcium excretion was 64.6 12.2
pEqI24 hr in the hyperparathyroid group and 31.9 1.8 Eq/24
hr in the controls (P < 0.02). Cumulative calcium excretion
tended to be higher in the hyperparathyroid group as well but
reached statistical significance only on day 6 when cumulative
calcium excretion from days 3 to 6 was 172.9 24.7 pEq/24 hr
in the hyperparathyroid group vs. 116.0 5.9 Eq/24 hr in the
control animals (P < 0.05). It should be noted that hypercalce-
mia is not sustained beyond 27 days in our study. This finding
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Fig. 1. Plasma calcium concentration prior to and following parathy.
roid gland transplantation (solid circles, solid lines) or SHAM surgery
(open circles, interrupted lines). Symbols are: +, P < 0.02, ** denote F
< 0.01, and § P < 0.001 when each group is compared. Data are
expressed as mean SEM.
I I I I
Hypercalcemia on renal acid base metabolism 615
was noted by Gittes and Wells [14] and attributed to either
involution of the transplanted glands or possible secondary
hypercalcitoninemia.
A decrease in plasma phosphorous developed within 3 days of
gland implantation. Basal plasma phosphorus was 6.32 0.05
mgldl in the experimental group and 6.39 0.23 mgldl in pair-
fed controls. By day 10, plasma phosphorus was 5.23 0.12
mgldl in the hyperparathyroid hypercalcemic rats vs. 6.38
0.12 mgldl in controls (P <0.001). However, unlike hypercalce-
mia and the alterations in acid balance, hypophosphatemia was
an inconsistent finding and was not present on all days of the
study. There was no difference in daily or cumulative phosphate
excretion between the two groups although phosphate clear-
ance tended to be higher in the hyperparathyroid animals.
Hyperparathyroid hypercalcemic animals developed meta-
bolic alkalosis which was first noted 6 days after gland trans-
plantation. On day 0 plasma total carbon dioxide was 23.46
0.54 mEq/liter in hyperparathyroid rats and 23.50 0.30 in
controls. On day 6 or 7 plasma total carbon dioxide was 25.44
0.47 mEq/liter in the hyperparathyroid group (P < 0.05 com-
pared to day 0) vs. 23.84 0.57 mEqlliter in the controls (P>
0.2 compared to day 0, P < 0.05 at day 6 to 7 when hyperpara-
thyroid and control groups are compared, Fig. 2). Correspond-
ing venous pH values were 7.44 0.01 in the hyperparathyroid
group vs. 7.39 0.02 in controls (P < 0.05). Calculated Pco2
values were 39.44 1.44 torr and 41.29 2.24 torr, respective-
ly (P > 0.1). The elevated serum bicarbonate concentrations
persisted for 10 days, but then the values between the two
groups tended to equalize.
We attempted to define better the factors responsible for the
development of alkalosis and to separate the roles of calcium
and parathyroid hormone. In a separate series of experiments in
a larger number of animals, plasma total carbon dioxide was
analyzed as a function of plasma calcium. While these studies
do not show animals and their pair-fed controls, they do provide
a large number of points in order to generate a correlation
between total carbon dioxide and plasma calcium. This correla-
tion was highly significant (r =0.73, P < 0.01) and was seen not
only when data from hyperparathyroid animals (N 14) and
pair-fed controls (N = 15) were pooled but also when the data
from hyperparathyroid animals and pair-fed control animals
were analyzed separately, (Fig. 3). The metabolic alkalosis may
be due, in part, to increased mobilization of alkaline bone salts,
but there is clear evidence that a renal mechanism is contribu-
tory. Daily acid excretion data are listed in Table I. As food
consumption by the hyperparathyroid animals decreased after
the implantation of glands, comparison was made between daily
acid excretion during the experimental period of pair-fed con-
trol to the mean daily acid excretion of hyperparathyroid rats.
Although there was no difference between hyperparathyroid
and control animals with respect to 24-hr urinary ammonia
excretion, urine pH was lower (6.72 0.04 vs. 6.95 0.04, day
5, P < 0.001), bicarbonaturia was less (165 26 vs. 283 28
mo1es/24 hr, day 5, P < 0.01), and titratable (164.2 43.4 vs.
4.82 2.53 iEq/24 hr, day 5, P < 0.01) and total acid excretion
(574.3 71.8 vs. 280.8 31.9 p.Eq/24 hr, day 5, P < 0.001)
were increased in the hyperparathyroid group. As shown in Fig.
4, cumulative acid excretion was higher in the hyperparathyroid
group from days 4 to 8, but daily acid excretion was increased
only on days 4 to 6, coincident with the development of
alkalosis (Fig. 5).
There was no difference in plasma or urinary creatinine,
plasma sodium, or potassium, GFR or fractional excretion of
sodium (FENa) between the two groups, as shown in Table 2. In
addition daily sodium excretion was measured in a subset of
hyperparathyroid rats (N = 6) and pair-fed, SHAM-operated
controls. Daily 24-hr urinary sodium excretion was not greater
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Fig. 2. Plasma total carbon dioxide concentration prior to and following
parathyroid gland transplantation. Symbols are ** denotes P < 0.05
when experimental rats are compared to SHAM-operated; other sym-
bols are defined in Fig. 1. Data are expressed mean 5EM.
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Fig. 3. Correlation of total carbon dioxide versus plasma calciu,n
concentration in hyperparathyroid (solid circles), and control ani,nals
(open circles). Solid line indicates data for all groups. Upper interrupted
line represents the value for hyperparathyroid animals, lower interrupt-
ed line, data for control animals (see text).
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Table 1. Urinary acid excretion in hyperparathyroid rats.
Basal
Day
1 2 3 4 5 6 7 8
Urine, pH
Hyperparathyroid 6.79 7.01 7.08 6.91 6.77 6.72 6.74 6.80 6.88
N = 10 P NS NS NS NS <0.01 <0.001 <0.01 NS <0.02
Control 6.55 6.99 7.06 6.96 6.96 6.95 6.97 6,89 7.10
N = 10 ±0.11 ±0.05 ±0.05 ±0.03 ±0.03 ±0.04 ±0.04 ±0.05 ±0.06
Ammonia Excretion, .mo1es/24 hr
Hyperparathyroid
P
1026.6
±59.8
NS
583.9
±37.9
NS
534.4
±45.5
NS
591.9
±20.1
NS
583.1
±27.7
NS
575.0
±29.0
NS
615.4
±29.3
NS
667.7
±30.2
NS
646.2
±50.6
NS
Control 865.1
±56.6
527.1
±72.9
637.2
±55.0
540.0
±29.8
573.6
±59.4
558.6
±25.1
549.9
±32.8
662.6
±48.2
613.4
±56.9
Bicarbonate Excretion, pmoles/24 hr
Hyperparathyroid
P
277
±33
NS
ND ND
300
±24
NS
199
±13
<0.01
165
±26
<0.01
180
±25
<0.02
220
±24
NS
262
±31
NS
Control 218
±35 ND ND
363
±56
352
±42
283
±28
302
±37
261
±32
388
±53
Titratable acid excretion, p.Eq124 hr
Hyperparathyroid
Control
P
136.5
±50.0
NS
148.5
±36.4
15.34
±15.34
NS
9.61
±9.61
undetectable
NS
58.9
±51.7
24.9
±24.9
NS
undetectable
97.2
±34.3
<0.05
18.6
±10.3
164.2
±43.4
<0.01
4.82
±2.53
153.4
±41.8
<0.01
24.4
±16.5
106.6
±40.7
NS
50.34
±39.9
34.5
±19.8
NS
11.6
±11.6
Total acid excretion, p.Eq124 hr
Hyperparathyroid
P
580.6
±107.0
NS
ND ND 319.9
±38.7
NS
464.7
±54,4
<.02
574.3
±71.8
<.001
589.2
±55.3
NS
580.8
±75.5
NS
418.4
±70.9
NS
Control 603.9
±76.6 ND ND
177.3
±76.2
240.9
±87.7
280.8
±31.9
267.5
±24.1
465.1
±86.1
236.6
±68.1
P value pertains to the difference between hyperparathyroid and pair-fed control for each parameter. All data are mean ± SEM. ND denotes that
a particular parameter was not determined.
Plasma creatinine, mg/d1 0.47 ± 0.02 0.46 ± 0.03
Creatinine clearance, mI/mm 1.80 ± 0.12 1.83 ± 0.12
Plasma sodium, mEq/!iter 135.1 ± 0.9 136.5 ± 1.0
FENa,% 1.3 ±0.1 1.1 ±0.1
Plasma potassium, i.Eq/!iter 4.85 ± 0.13 4.84 ± 0.21
A significant statistical difference was not found between hyper-
parathyroid animals and controls, N represents the number of animals
in each group.
in the transplanted hyperparathyroid rats on any day of the
study. These data suggest that contraction of the extracellular
fluid volume did not contribute to the metabolic alkalosis.
1,25(OH)2 Vitamin D-induced hypercalcemia. To attempt to
separate the effects of hyperparathyroidism from those of
hypercalcemia, we induced hypercalcemia by treatment with
1,25(OH)2 vitamin D (N = 14). Although no effect was seen
after 4 day's treatment, by day 7 marked and persisting hyper-
calcemia developed (Table 3). In addition, values were signifi-
cantly higher in the 1 ,25(OH)2-vitamin D-treated animals com-
pared to baseline 5.81 ± 0.04 to 6.50 ± 0.11 mEq/liter P <
0.001. Hypercalciuria was sustained and profound with an
approximate 20-fold rise in 24-hr urine calcium excretion in
vitamin D-treated rats (436 ± 35 .Eq/25 hr) when compared to
pair-fed controls (20.4 ± 2.3 Eq/24 hr, P < 0.001).
As compared to pair-fed controls, 1 ,25(OH)2-vitamin D-
treated animals developed hyperphosphatemia by day 7 of the
treatment which persisted for the duration of our study, as
shown in Table 3. On day 10, fractional phosphate excretion
was 6.15 ± 0.60% in the 1 ,25(OH)2-vitamin D-treated group vs.
7.79 ± 0.45% in the controls (P < 0.05). This difference
presumably reflects the suppression in PTH secretion induced
by vitamin D and hypercalcemia.
Similar to the animals with hyperparathyroid-induced hyper-
calcemia, the vitamin D-treated group developed a metabolic
alkalosis which persisted throughout our study. On day 7,
plasma total carbon dioxide had risen from 28.25 ± 0.61 to 30.35
± 0.66 mEq/liter (P < 0.05) in I ,25(OH)2-vitamin D-treated
animals but was unchanged in controls (P > 0.2). On day 10,
plasma total carbon dioxide was 28.88 ± 0.44 mEq/liter in the
vitamin D group vs. 25.91 ± 0.36 mEq/liter in the controls (P <
Table 2. Other renal function parameters in hypercalcemic
hyperparathyroid animals and pair-fed controls on day 7a
Hyperparathyroid Pair-fed controls
animals N = 10 N = 10
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Fig. 4. Cumulative 24-hr urinary total acid excretion in hyperparathy-
roid hypercalcemic rats (shaded bars) and pair-fed controls (open bars).
When the two groups are compared, symbols represent, ", P<0.05, **
denoteP < 0.02; § denotes P < 0.01; ND, not determined.
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Fig. 5. Daily 24-hr urinary total acid excretion in hyperparathyroid
hypercalcemic animals (closed bars) and pair-fed controls (open bars).
When the two groups are compared, the symbols represent, , P < 0.05;
** denote P < 0.02; § denotes P < 0.01.
0.001, Fig. 6). Corresponding venous pH values were 7.43
0.02 in the experimental group and 7.40 0.02 (N = 5) in the
control group. Plasma Pco2 in the two groups was similar, 46.86
1.04 ton and 47.01 3.13 ton, respectively. Although
plasma pH in the hypercalcemic group was not significantly
higher than pH in the control group, the similarities in Pco2
levels suggest that the increase in measured venous total carbon
dioxide was due to metabolic alkalosis and not due to chronic
compensation for hypercapnea. Alkalosis persisted through day
13, at which time the study was terminated. Although the
alkalosis may in part have been generated by increased absorp-
Basal Day 7 Day 10 Day 13
FIg. 6. Plasma total carbon dioxide in 1 ,25(OH)2 vitamin D-treated rats
(solid circles) and pair-fed controls. Symbols are, ** P < 0.001, §
denotes P < 0.02. Data are expressed as mean SESI.
200
0 tion of alkali from the gut or increased bone resorption,
augmented renal acid excretion contributed to the alkalosis
(Table 4). Urine pH was lower (6.34 0.09 vs. 7.12 0.04day
7, P < 0.001), bicarbonaturia less (39.4 9.0 vs. 107.3 17.9
amoles/24 hr, day 7, P < 0.01), and titratable acid (267.9 34.7
vs. 1194 92.4 p.Eq124 hr, day 7, P < 0.001) and total acid
excretion greater (1442.5 86.7 vs. 330.1 42.6Eq/24 hr, day
7, P < 0.001) in the 1 ,25(OH)2-vitamin D-treated group. A plot
of serum calcium versus total carbon dioxide in these animals
also revealed a linear correlation (r = 0.69, P < 0.001) as noted
for hyperparathyroid hypercalcemic animals.600 Plasma sodium, potassium, and creatinine concentrations as
well as fractional excretion of sodium were similar in hypercal-
400 cemic 1 ,25(OH)2-vitamin D-treated and control animals. Creati-
nine clearance in vitamin D-treated animals and controls was
— 200 similar before treatment but values in control animals fell after
day 10, as shown in Table 5.
Urinary cyclic AMP excretion was determined in hypercalce-
mic hyperparathyroid and hypercalcemic 1 ,25(OH)2-vitamin D-
treated animals. It was 0.055 0.1 jmoles/8 hr in the hyperpar-
athyroid animals (N = 5) vs. 0.030 0.004 mo1es/8 hr in the
1,25 dihydroxy vitamin D-treated animals (N = 10, P < 0.01)
confirming relative suppression of PTH secretion in the latter
group compared to the hyperparathyroid group.
Discussion
The results of our study suggest that metabolic alkalosis
occurs in two models of chronic hypercalcemia, experimental
primary hyperparathyroidism and chronic 1 ,25(OH)2-vitamin D
administration, and that it is due, at least in part, to a renal
tubular effect. Because PTH secretion is known to be markedly
different in these two forms of hypercalcemia, as suggested by
differences in phosphate clearance, cAMP excretion, and PTH
measurements, it is likely that the observed alterations in renal
tubular hydrogen ion handling are related to a direct effect of
the calcium ion per se.
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Table 3. Effects of I ,25(OH)2 vitamin D on serum and urine calcium and phosphatea
Basal Day 7 Day 10 Day 13 Basal Day 7 Day 10 Day 13
Serum calcium, mEqiliter Urine calcium, Eq/24 hr
1,25(OH)2D3 treated 5.81 6.50 6.66
±0.11
6.87 21.4 436.4 376.6 377.5'
Controls 5.77 5.78" 5.62"
Serum phosphate, mg/dI
5.76 17.4 20.4' 18.4'
Urine phosphate, pg/24 hr
26.7'
l,25(OH)2D3 treated 7.76 8.24 6.79 8.75 6430.4 5467.0 4336.7 ND
Controls 7.65 6.36" 5.63 6.58" 6082.4 5235.4 3494.6
ND
a In statistical comparison of l,25(OH)2D3 treated versus control animals: b P < 0.01. P < 0.001. ND denotes that data was not collected.
Table 4. Urinary acid excretion in 1 ,25(OH)2 vitamin D3-treated ratsa
Basal Day 7 Day 10 Day 13
Urine pH
l,25(OH)2D3 treated 6.96 6.34 6.24 6.48
Control 7.06 7.12c 7.30' 7.19'
l,25(OH)2D3 treated 199.3
Ammonia excretion, p.moles/24 hr
288.0 557.1 281.3
Control 196.7 169.5k' 325.2 219.4
1,25(OH)2D3 treated 102.5
Bicarbonate excretion, p.molesI24 hr
39.4 45.4 88.6
Control 110.5
18.6
107.3" 162.2'
17.9
155.2
l,25(OH)2D3 treated 595.5
Titratable acid excretion, pEq/24 hr
1194.9 1156.8 1103.3
Control 465.6 267.9' 161.2' 283.4"
l,25(OH)2D3 treated 692.3
Total acid excretion, p..Eq124 hr
1442.5 1792.7 1296.5
Control 551.8 330.1' 325.2' 347.6'
'For statistical comparison of I ,25(OH)2D3-treated versus control animals: b p < 0.02; 'P < 0.001.
It must be emphasized that in these studies an alkalinizing
process is ongoing and is due, in part, to increased net renal
acid excretion. The changes in plasma total carbon dioxide seen
in these experiments are relatively small, but these of course
are influenced by a variety of factors including extrarenal
disposition of acid, gastrointestinal alkali transport, and endog-
enous metabolic activity. Thus, while in these particular expen-
ments changes in plasma acid-base parameters were relatively
small, the renal effects were quite striking and suggest that high
levels of extracellular fluid calcium, as induced by two separate
manipulations of calcium metabolism, lead to increased renal
acid excretion.
Previous studies of the effects of calcium on renal function
have been performed during acute or subacute calcium infu-
sions when alterations in renal blood flow occurred [12] or
during reduction in GFR [16]. Nonetheless, such data generally
support the results of our studies. Acute hypercalcemia has
been shown to stimulate bicarbonate reabsorption during bicar-
bonate titration experiments [12], thus implying an increase in
hydrogen secretion. The mechanism whereby hypercalcemia
produces these effects is unclear. Potassium depletion or hyper-
capnea cannot explain the current results because these
changes were sought specifically and excluded. While alteration
of gastrointestinal absorption or the release of alkaline bone
salts may have contributed to the rise in serum bicarbonate
concentration, there clearly was a direct renal contribution, as
seen in Tables 1 and 4 and Figure 4. These data suggest that
hypercalcemia leads to an increased renal net acid excretion by
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Table 5. Glomerular function and serum electrolyte parameters in
I ,25(OH)2 vitamin D-treated rats
Day
I ,25(OH)D3-
treated
Pair-fed
controls
Plasma creatinine, mg/dl 0
10
0.69 0.05
0.80 0.09
0.66 0.05
0.80 0.07
Creatinine clearance, mI/mm 0
10
0.78 0.08
0.82 0.11
0.83 0.10
0.56 0.06a
Plasma sodium, mEq/liter 10 141.8 1.1 143.3 0.1
FENa, % 10 0.9 0.1 1.2 0.1
Plasma potassium 10 3.9 0.2 4.2±0.1
a Significantly different from experimental group at P < 0.05 level.
lowering urine pH and reducing bicarbonate excretion. The rise
in titratable acid excretion is due primarily to these effects,
rather than to an increase in the excretion of urinary buffers.
Interestingly, ammonia excretion did not rise despite the fall in
urine pH. Previous in vivo [17] and in vitro studies of this issue
[18] have suggested that calcium may reduce renal ammonia
production directly. However, a direct effect of systemic alka-
losis to reduce ammonia production cannot be excluded. It
should be emphasized in these studies that total acid excretion
was reduced in the hypercalcemic models primarily by a
reduction in urinary bicarbonate excretion. Whether the mecha-
nism of this effect represented a stimulation in bicarbonate
reabsorption or, more likely, an increase in hydrogen ion
secretion, as manifested by the lower urinary pH, cannot be
determined. However, it must be noted that ammonia excretion
was not affected by these factors. While similarities in sodium
excretion between hypercalcemic and control groups were used
as an indicator of an absence of extracellular fluid volume
contraction, it should be noted that small decreases in either
plasma volume or total extracellular fluid volume could lead to
increased renal bicarbonate reabsorption and could account for
part of the enhanced acid excretion seen in these studies. While
this seems unlikely, our data do not exclude this possibility.
From data in animals with hyperparathyroid hypercalcemia
as well as control animals, it was possible to construct a plot
relating serum calcium to serum bicarbonate level (Fig. 3).
These highly significant correlations, in the absence of other
factors known to influence hydrogen ion excretion, suggest a
linear dose-response effect of calcium on renal hydrogen secre-
tion. This observation possibly supplies a new basis for clinical
observations of alkalosis in chronically hypercalcemic patients.
The effects of hypercalcemia induced by hyperpara-
thyroidism or by 1 ,25(OH)2-vitamin D administration were
similar in that the rise in serum bicarbonate was accompanied
by a rise in titratable acid excretion and a fall in urinary pH and
bicarbonate excretion. However, the effect of PTH-induced
hypercalcemia persisted for 10 days while that of 1,25(OH)2-
vitamin D persisted for the duration of observation. Whether
these differences may be the result of a higher level of hypercal-
cemia achieved in the l,25(OH)2-vitamin D-treated animals, a
direct effect of 1 ,25(OH)2-vitamin D independent of hypercalce-
mia or other unknown factors cannot be determined. It should
also be noted that ionized calcium concentrations were not
measured in our studies. It is possible that differences in this
parameter due to differing bicarbonate or plasma albumin
concentrations may have occurred between the two groups. It
is also possible that elevated levels of VFH in the hyperpara-
thyroid rats counteract some of the alkalinizing effect of hyper-
calcemia as discussed below.
Previous studies of the acute renal effects of PTH by micro-
perfusion [19, 20] and micropuncture [6, 21] have repeatedly
shown that the hormone leads to inhibition of bicarbonate
reabsorption in the more proximal portions of the nephron. In
addition, clearance studies have shown that on occasion, uri-
nary pH rises and bicarbonate excretion increases following
PTH infusion [22], but this finding is not universal. These
observations were used to explain the finding of hyperchlore-
mia in populations of patients with primary hyperpara-
thyroidism [7]. In this formulation, PTH reduces renal bicar-
bonate reabsorption directly and thereby generates a hyper-
chloremic metabolic acidosis. However, careful prospective
studies have failed to show metabolic acidosis in patients with
primary hyperparathyroidism [8]; concurrent renal insufficien-
cy [7] and hypophosphatemia [11] may each contribute to
metabolic acidosis in patients with hyperparathyroidism. Our
studies also suggest that chronic elevations of PTH have
markedly different effects on acid-base balance than acute
infusions of the hormone. It would appear that the alkalinizing
effects of hypercalcemia may moderate any acidifying effect of
PTH. However, our data fail to demonstrate any direct evi-
dence of such a role for PTH. Moreover, even the previously
noted studies utilizing acute pharmacologic infusions of PTH in
the rat have failed to show a rise in bicarbonaturia despite a
clear reduction in proximal tubular bicarbonate reabsorption
[6]. Also, Beck et al [23], have shown that hypercalcemia may
antagonize the renal effects of PTH to increase cAMP produc-
tion so that it is possible that calcium and PTH may have
opposing actions on renal hydrogen ion handling. Taken togeth-
er, these data suggest that chronic elevations of PTH exert a
minor, if any, direct effect to alter renal bicarbonate handling.
Alternative explanations may be forwarded for our results.
First, because 1,25(OH)2-vitamin D levels are elevated in
hyperparathyroidism [24] and presumably during the adminis-
tration of large amounts of exogenous 1 ,25(OH)2 vitamin D, it is
possible that this hormone has a direct effect on the renal tubule
to stimulate bicarbonate transport. Acute studies have demon-
strated an effect of 25-OH-vitamin D to stimulate renal bicar-
bonate reabsorption in intact dogs [25]. Whether or not this
finding explains the current data is unknown. Non-PTH, non-
vitamin D-associated hypercalcemia would be required to test
this hypothesis specifically. Also, it is possible that chronic
elevations of PTH, I ,25(OH)2-vitamin D, or calcium lead to
changes in the secretion or elaboration of hormones such as
aldosterone, prostaglandins, or kinins which in turn alter tubu-
lar hydrogen secretion. While the absence of changes in potassi-
um or sodium handling renders such a view unlikely, only
studies employing specific hormonal ablation or competitive
inhibitors of hormone action can resolve these questions.
Summary. Hyperparathyroid-induced chronic hypercalcemia
leads to an elevation of serum bicarbonate level in the rat.
Because 1,25 OHD2-vitamin D-induced hypercalcemia has a
similar effect, it is concluded that hypercalcemia per se stimu-
lates net renal acid excretion. The interactions between PTH,
1 ,25(OH)2-vitamin D, and hypercalcemia in modulating these
effects and the specific tubular sites and mechanisms of these
phenomena remain unclear. However, the data do suggest a
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possible role of hypercalcemia in modulating chronic changes in
renal acid-base metabolism.
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